Establishing a Long Island Bioscience Hub

建立长岛生物科学中心

基本信息

批准号：
8880529
负责人：
CLINTON T RUBIN
金额：
$ 100万
依托单位：
STATE UNIVERSITY NEW YORK STONY BROOK
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-03-20 至 2018-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8880529
关键词：
Address Agreement Award Basic Science Biological Sciences Biomedical Research Biomedical Technology Biotechnology Businesses Camping Capital Communities Complement Computed Tomographic Colonography Development Devices Diagnostic Disclosure Economics Education Educational workshop Engineering Entrepreneurship FDA approved Faculty Fostering Foundations Funding Goals Hand Health Healthcare Human Human Resources Incentives Incubators Industry Institutes Institution Intellectual Property Investments Laboratories Laws Lead Left Legal Licensing Lilly brand of abciximab Long Island Mediation Medical Medical Device Mentors New England Outcome Periostat Pharmacologic Substance Pharmacopoeias Plant Roots Positioning Attribute Postdoctoral Fellow Process Provider Recruitment Activity Research Research Infrastructure Resources Risk Science Seasons Secure Seeds Services Side Small Business Innovation Research Grant Small Business Technology Transfer Research Staging Statutes and Laws Structure System Talents Taxes Technology Technology Transfer Testing Therapeutic Training Training Programs Translating Translational Research Translations Universities Work base commercialization experience graduate student improved innovation innovative technologies interest manufacturing scale-up next generation outreach pre-clinical research programs residence small molecule success technology development

项目摘要

DESCRIPTION (provided by applicant): An exceptional opportunity exists within the academic sector to promote human health through the development, translation and commercialization of basic discoveries which arise from the biomedical research enterprise of our academic institutions. Unfortunately, the process by which innovations are identified, translated, developed, and ultimately commercialized is still far from optimal, leaving the full economic and societal benefit from the region's intellectual capital unrealized. To address this need, we propose to form a regional partnership comprised of Stony Brook University (SBU), Cold Spring Harbor Laboratory (CSHL) and Brookhaven National Laboratory (BNL). These institutions have a demonstrated capacity for bioscience innovation that has advanced the course of biomedical science and contributed to improved healthcare through FDA approved therapies including ReoPro(r), SAFHS(r), Xiaflex(r), Periostat(r) and Oracea(r), new medical devices including 3D- virtual colonoscopy and LivMD(r), and new company formation including New England BioLabs, OSI Pharmaceuticals, Collagenex, Pharmacopeia, Exogen and Set Point Medical. Through four specific aims, this State (SBU), Private (CSHL) and Federal (BNL) partnership will build upon existing strengths in translational biomedical research and commercialization to: A) Develop an infrastructure and implementation system, B) Increase the yield of new healthcare innovations from within our basic biomedical research enterprise, C) Fuel new biotech, pharma and medical device company formation rooted within the region, and D) Train next generation bio-entrepreneurs to lead these ventures. In aggregate, these objectives will provide the foundation for a vibrant bioscience industry cluster that will foster an ever-expanding Long Island Bioscience Hub (LIBH).

描述（由应用程序提供）：学术领域中存在一个非凡的机会，可以通过基本发现的发展，翻译和商业化来促进人类健康，这些发现来自我们学术机构的生物医学研究企业。不幸的是，确定，翻译，开发和最终商业化的创新过程远非最佳，使该地区知识分子资本的全部经济和社会利益远离未实现。为了满足这一需求，我们建议建立由Stony Brook University（SBU），Cold Spring Harbour Laboratory（CSHL）和Brookhaven国家实验室（BNL）组成的区域合作伙伴关系。这些机构具有生物科学创新的能力，它推进了生物医学科学的进步，并通过FDA批准的疗法改善了医疗保健，包括Reopro（R），Safhs（R），Xiaflex（R），Pererostat（R），骨膜（R），Oracea（R）和Oracea（R）（R），包括3D- NEW COLLOUT COLONSCOPPY和LIV NEW COMPLIATION（包括新的医疗机构）（包括新的医疗式）（包括新的医疗机构）（包括新医疗机构）和RIV M. Biolabs，OSI Pharmaceuticals，Collagenex，Pharmacopeia，Exogen和Set Point Medical。通过四个具体目标，该状态（SBU），私人（CSHL）和联邦（BNL）伙伴关系将基于转化生物医学研究和商业化的现有优势：生物企业家领导这些企业。总体而言，这些目标将为充满活力的生物科学行业集群提供基础，该集群将促进一个不断扩大的长岛生物科学枢纽（LIBH）。